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1. Introduction 
Platelets and other coagulation factors play an important role in the primary haemostasis 
mechanism, a multistep process of platelets interaction with elements of the damaged vessel 
wall, leading to the initial formation of a platelet plug (Ahmad et al., 2008). This mechanism 
requires the synergistic action of several different platelet receptors which play an essential 
role in each step of aggregation. Platelet adhesion, activation and aggregation are in fact 
regulated by specific glycoprotein on the platelet cell surface. Genetic defects in one of these 
glycoprotein led to bleeding symptoms due to inability of blood platelets to provide their 
hemostatic function in the vessel injury.  
Inherited platelet defects cause bleeding symptoms of varying severity. Typically, easy 
bruising, epistaxis, gingival and mucocutaneous bleeding are observed in affected patients.   
Different diagnostic parameters have been used to classify inherited thrombocytopenia 
including the degree of bleeding, inheritance trait, platelet function and kinetics, and clinical 
abnormalities (see table 1).  
The platelet defects are classified into disorders affecting either intracellular organelle of 
platelets, signalling pathway or surface receptors.  
Currently, much effort is being put into methods to more rapidly and accurately diagnose 
patients with platelet disorders and to initiate appropriate therapy and prevent life 
threatening bleeding (Simon et al., 2008). 
In this chapter, we describe many platelets disease caused by secretion defects like in Grey 
Platelet Syndrome (GPS), Quebec platelet disorder (QPD) or Wiscott-Aldrich syndrome 
(WAS), other diseases due to signal transduction shortcoming. Finally, we detail 
some diseases caused by deficiency of platelet complex expression in the cell surface and we 
develop especially Bernard Soulier syndrome (BSS). 
2. Defects of secretion 
Many disorders are classified in this category and are known as “storage pool disease”. This 
group contain several congenital diseases characterized by defects in intracellular organelle 
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especially α-granule and dense granule (Simon et al., 2008)..The absence of platelet granules 
results in a defective secretion from activated platelets as well as abnormal secretion-
dependent platelet aggregation (Sandrock & Zieger, 2010).  
Deficiencies can alter the contents of α-granules, dense granules or both. In many patients 
the storage pool defect is the only abnormality detected. Nevertheless, the association with 
other congenital abnormalities was also shown like in Hermansky-Pudlak syndrome (HPS), 
Chediak-Higashi syndrome (CHS) and Wiskott-Aldrich syndrome (David et al., 2001). 
 
Syndrome Bleeding 
symptoms 
Platelet 
count 
(109/l) 
Platelet 
aggregation 
Inheritance Gene 
GPS Mild to 
moderate 
30-100 normal or 
↓ aggregation 
with thrombin,
collagen 
autosomal 
recessive 
(most) 
or dominant 
unknown 
QPD Mild to 
moderate 
Normal 
or less 
↓ aggregation 
with 
epinephrine 
Autosomal 
dominant 
uPA gene 
(PLAU) 
HPS Moderate 
to severe 
normal ↓ second wave 
of aggregation 
Autosomal 
recessive 
HPS1-HPS8 
CHS Moderate 
to severe 
normal ↓ second wave 
of aggregation 
Autosomal 
recessive 
LYST 
WAS Moderate 
to severe 
10-100 ↓ aggregation X-linked 
recessive 
WAS 
XLT moderate decreased ↓ aggregation X-linked WAS 
GT Moderate to
severe 
Normal Reduced or 
absence of 
aggregation 
Autosomal 
recessive 
GPIIb and 
GPIIIa 
BSS Moderate to
severe 
10-100 Absence of 
Aggregation 
with ristocetin 
Autosomal 
recessive 
(most) 
or dominant 
GPIbα, 
GPIbβ and 
GPIX 
Table 1. Clinical symptoms and candidate genes of several inherited platelet diseases 
2.1 Abnormalities of α-granule  
2.1.1 Grey Platelet Syndrome 
The first case has been reported by Raccuglia in 1971 as a qualitative defect in platelets 
(Raccuglia, 1971). This rare hereditary disease is characterized by a bleeding tendency, 
moderate thrombocytopenia and decrease or absence of platelet ǂ-granules and their 
contents probably due to the failure of maturation during megakaryocyte differentiation 
(White, 1979). GPS platelets are unsuitable to get and store endogenously synthesized 
proteins such as platelet factor-4, ǃ-thromboglobulin, Von Willebrand Factor (vWF) as well 
as exogenous proteins such as fibrinogen, albumin, or factor V (Sandrock & Zieger, 2010). 
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Microscopic observations of patients blood smear revealed mild to moderate 
thrombocytopenia and enlarged (but not giant) platelets that have a gray appearance. 
Platelet aggregation studies are variable with no classical response pattern to ADP, 
epinephrine, thrombin, or collagen (Nurden, 2007). 
Both autosomal recessive and autosomal dominant inheritance have been reported 
suggesting that this syndrome is genetically heterogeneous (Mori et al, 1984) (Nurden et al., 
2004). The molecular basis of GPS is unknown but could involve a “sorting” receptor for 
vesicles leaving the Golgi apparatus (Nurden, 2005). 
2.1.2 Quebec platelet disorder 
Quebec platelet disorder (QPD) is a defect in ǂ-granule proteolysis of proteins and a 
deficiency of ǂ- granule multimerin, a protein that binds factor V within the granule, thus 
leading to a decreased content of platelet factor V along with several other proteins like 
fibrinogen and vWF (Shapiro, 1999). 
In addition to α-granule protein degradation, this inherited bleeding disorder is associated 
with increased expression and storage of the fibrinolytic enzyme urokinase plasminogen 
activator (uPA) in platelets and intra-platelet plasmin generation (Diamandis et al., 2009). 
Patients showed mild thrombocytopenia, absence of aggregation with epinephrine and 
moderate to severe delayed bleeding following trauma or surgery that responds only to 
fibrinolytic inhibitor therapy (Veljkovic et al., 2009). 
This syndrome is inherited as an autosomal dominant manner. The genetic cause of QPD 
has recently been linked to inheritance of a region on chromosome 10 that contains the uPA 
gene (PLAU) (Diamandis et al., 2009). 
2.2 Abnormalties of dense granule 
Dense granule deficiency is often, but not always, associated with impaired secondary 
aggregation responses to some agonists (Ahmad et al., 2008). 
2.2.1 Hermansky-Pudlak syndrome 
Hermansky–Pudlak syndrome (HPS) is a rare autosomal recessive disorder. First HPS cases 
were reported on 1959 by Hermansky and Pudlak: Two unrelated patients suffered from 
oculocutaneous albinism, a history of frequent bruising following minimal trauma, lifelong 
bleeding tendency and unusual pigmented macrophages in bone marrow (Hermansky & 
Pudlak, 1959). 
This syndrome results from abnormal formation or trafficking of intracellular vesicles. The 
specific organelles affected in HPS are the lysosomes and lysosome-related organelles such 
as the melanosomes and the platelet dense granule (Cutler, 2002). 
Clinical manifestations showed hypopigmentation, platelet dense granule deficiency and 
accumulation of ceroid pigment in lysosomal organelles (Ramasamy, 2004).  
HPS patients have been described in different ethnic groups. However, this syndrome is 
frequent in Puerto Rico and in an isolated mountain village in the Swiss Alps (Schallreuter 
et al., 1993; Witkop et al., 1990). 
Eight human HPS genes (HPS1–HPS8) have been found causing hypopigmentation and 
platelet storage pool deficiency. All HPS proteins are associated in multi-protein complexes 
essential for biogenesis and intracellular trafficking of intracellular vesicles of lysosomal 
lineage (Li et al., 2004). Mutations within particular HPS genes can lead to dysfunction of 
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the corresponding protein complex and thus to defective maturation of melanosomes and 
platelet dense bodies (Sandrock & Zieger, 2010). 
2.2.2 Chediak-Higashi syndrome 
Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disease described since 1955 
by Sato (Sato, 1955). Like HPS, CHS is also characterized by oculocutaneous albinism and 
dense granule deficiency leading to platelet disorder and prolonged bleeding tendency. In 
addition, CHS patients showed severe immunologic defects and progressive neurological 
dysfunction making this disease lethal. If patients survive until adulthood, they develop 
neurological defects including neuropathies, autonomic dysfunction, atrophy, sensory 
deficits, seizures, and cognitive defects (Sandrock & Zieger, 2010). Only hematopoietic stem 
cell transplantation can improve the health status of patients (Eapen et al., 2007). 
The canditate gene for this syndrome is named LYST (lysosomal trafficking regulator) 
(Barbosa et al., 1996; Nagle et al., 1996). The gene product is a protein which regulates the 
size and movement of lysosome-related organelles. LYST is predicted to be a cytosolic 
protein that mediates membrane interactions. Genetic defects are usually frameshift and 
nonsense mutations in LYST gene giving rise to truncated protein and a severe phenotype 
(Certain et al., 2000; Moore et al., 2002). Rarely, missense mutations are associated with a 
milder form of the disease. 
2.3 Abnormalities of both granules 
2.3.1 Wiskott-Aldrich syndrome 
Wiskott–Aldrich syndrome (WAS) is a rare X-linked recessive disease. The inheritance of 
this syndrome explains why symptomatic individuals were all male (Aldrich et al., 1954). 
This syndrome has been observed first in 1939 by Alfred Wiskott. This paediatrician 
described three brothers who suffer from thrombocytopenia, bloody diarrhea, eczema, and 
recurrent ear infections; all three died early in life from intestinal bleeding and sepsis 
(Wiskott et al., 1939). The WAS phenotype consists of immunodeficiency, eczema, 
thrombocytopenia and is associated with extensive clinical heterogeneity. The immune 
deficiency is caused by decreased antibody production, although T cells are also affected 
(Vera Binder et al., 2006). 
WAS is caused by mutations in WAS gene located at Xp11.22–p11.23, encoding Wiskott-
Aldrich syndrome protein (WASP). This protein seems to be involved in signal transduction 
pathways in which tyrosine phosphorylation and adapter protein function have been 
suggested. Deficiency of WASP induces premature proplatelet formation in the bone 
marrow and cancels megakaryocytes migration (Sabri et al., 2006). 
WASP is involved in innate immunity, cell motility and protection against autoimmune 
disease. The success of hematopoietic stem cell transplantation is related to the patient’s age, 
donor selection, the conditioning regimen and the extent of reconstitution. Gene therapy is 
expected to cure the disease because WASP is expressed exclusively in hematopoietic stem 
cells and it exerts a robust selective pressure (Notarangelo et al., 2008).  
2.4 X-linked thrombocytopenia 
X-linked thrombocytopenia (XLT) was recognized in 1960 and was suspected to be a variant 
of WAS. This was confirmed when XLT patients showed mutations in the WAS protein 
gene.  
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XLT patients have moderate symptoms when compared with WAS. They showed mild 
eczema and/or infections and they have a lower risk of cancer or autoimmunity than 
patients with WAS. XLT phenotype is often resulting from missense mutations given rise to 
defective expression of WASP (Albert et al., 2010). 
3. Defects of intracellular signalling pathway 
For many patients with platelet aggregation defects, the abnormalities lie in early signal 
transduction events. Those patients have a prolonged bleeding time on most occasions, they 
have an impaired dense granule secretion although their platelets have normal granule 
storage and generally synthesise substantial amounts of thromboxane A2 (Ramasamy, 2004). 
Platelet pathologies involving the signal transduction pathways mostly concern patients 
with mild bleeding disorders and defects of platelet aggregation which affect some stimuli 
more than others.  
Concerned patients showed: 
Impaired Ca2+ mobilisation.  
Defective inositol-triphosphate production and a reduced phosphorylation of the protein, 
plekstrin, by protein kinase C. 
Deficiency of the phospholipase C-Ǆ2 isoform,  
Specific decrease in platelet membrane Gǂq and decrease in platelets response to several 
agonists including a decreased activation of ǂIIbǃ3.  
A major effort is underway to uncover the genetic defects responsible of these phenotypes. 
(Nurden & Nurden, 2008) 
4. Disorders of the surface membrane 
Most studied disease affecting membrane receptors are Bernard Soulier syndrome which 
concern GPIb-IX-V complex and Glanzmann thrombasthenia with deficiency in GPIIb-IIIa 
complex.  
4.1 Glanzmann thrombasthenia 
Glanzmann thrombasthenia (GT) is the most common of the platelets diseases. It is 
characterized by the absence or deficiency of GPIIb-IIIa platelet complex. This complex play 
an essential role in platelets aggregation by fixing several ligand, like von Willebrand Factor 
and fibrinogen (Bellucci et al., 1983; Giltay et al., 1987). GP IIb–IIIa is one of the most 
abundant platelet surface receptors (about 80 000 per platelet) (Wagner et al., 1996). 
The patients present normal platelet morphology, prolonged bleeding time, severe 
mucocutaneous diasthesis and series of epistaxis, purpura or menorrhagia (Sherer & Lerner, 
1999). The hallmark of this disease is a severely reduced or absent platelet aggregation in 
response to multiple physiological agonists such as ADP, epinephrine, thrombin and 
collagen. (Ahmad et al., 2008). 
This disease is inherited as an autosomal recessive manner (Sherer & Lerner, 1999). Genetic 
defects are distributed in GPIIb or GPIIIa genes resulting in qualitative or quantitative 
abnormalities of the proteins. Both genes are present in our genome as single copies and are 
localized on chromosome 17 (table 2) (Rosenberg et al., 1997). More than 70 mutations have 
been described. Large deletions are very rare. Most of them are missense or nonsense 
mutation, insertion, small deletion and splicing defects; some of the punctual mutations 
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affected the mRNA production or stability (Nurden, 2005). This large number of identified 
mutations offers an opportunity to investigate phenotype/genotype correlations 
(Ramasamy, 2004). 
 
 GPIIb GPIIIa 
Size (Kb) 17 65 
Number of exons 30 15 
Chromosome Localisation 17q21-23 17q21-23 
Table 2. Characteristics of GPIIb and GPIIIa genes 
4.2 Bernard Soulier syndrome 
4.2.1 History  
BSS was described more than 60 years ago as a severe and potentially fatal, congenital 
bleeding disorder. The first case was reported in 1948 by two French hematologists (Jean 
Bernard and Jean-Pierre Soulier) in a young male patient from a consanguineous family 
with severe bleeding episodes, a prolonged bleeding time, low platelet counts and very 
large platelets. They termed the disorder ‘‘congenital hemorrhagiparous thrombocytic 
dystrophy’’ (Bernard & Soulier, 1948). Since then, several individuals have been described 
with a similar disorder.  
4.2.2 Clinical manifestations 
BSS patients present early many bleeding symptoms, most commonly epistaxis, ecchymosis, 
cutaneous and gingival bleeding. Some patients can show gastrointestinal haemorrhage. 
Severe bleeding occurred in the case of trauma, surgical intervention and in menses (Lanza, 
2006). Chronic easy bruising and frequent hematomas are rarely reported (Kenny et al., 
1999). Pregnancy in BSS patients may present complications of varying gravity. 
The severity of these bleeding symptoms is variable among patients and may range from 
mild to life-threatening and may become more or less severe during puberty and adulthood. 
Some rare BSS patients suffered fatal haemorrhage (Hadjkacem et al., 2010a). Heterozygous 
patients may have mild to moderate bleeding tendencies (Pham & Wang, 2007).  
4.2.3 Etiology 
The molecular defect alters platelet complex named GPIb-IX-V. It is the surface receptor for 
von Willebrand factor that mediates both platelet agglutination in response to ristocetin and 
platelet adhesion under conditions of rapid blood flow. This complex plays an essential role 
in primary haemostasis ensuring platelets adhesion by its binding to von Willebrand factor, 
itself captured from plasma by sub-endothelial collagen (Berndt et al., 1989). 
GPIb-IX-V complex is composed by four glycoproteins designated GPIbα, GPIbβ, GPIX and 
GPV. They are expressed on the platelets surface in an apparent molar ratio of 2:2:2:1 
respectively (figure 1). Approximately, 24000 copies of this complex are presents on the 
membrane of activated platelets (Strassel et al., 2009). 
GPIbǂ, consists of 610 amino acids (MW 145 kDa), GPIbǃ of 181 (22 kDa), GPIX of 160 (20 
kDa), and GPV of 544 amino acids (82 kDa). GPIbα is disulfide linked to GPIbβ constituting 
GPIb dimer while GPIX and GPV bind to GPIb non-covalently (Lopez et al., 1998). 
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The vWF binding domain is located at the N-terminus of GPIbǂ. The GPIbǂ chain also 
binds a number of other ligands, including thrombin. The GPIbβ protein has N-terminal 
extra cellular domain that contains a cysteine knot region, which is essential for 
interaction with GPIX. The letter is essential for the correct assembly of the GPIb-IX-V 
complex on the platelet membrane. GPV is required for thrombin binding, possibly 
through an interaction with GPIbǂ. In addition, GPV binds to collagen and appears to be 
required for normal platelet responses to this agonist (Dong et al., 1998; Lopez et al., 
1998). 
 
 
Fig. 1. GPIb-IX-V complex 
The GPIb-IX-V complex is formed within minutes in the endoplasmic reticulum before 
being transported into the Golgi cisternae to undergo post-translational modifications. Only 
complete complexes were expressed on the platelets membrane. The absence of one 
component of the complex increases the rate of degradation (Dong et al., 1998) 
4.2.4 Diagnosis 
The diagnosis is based on the presence of a prolonged skin bleeding time (more then 15 
min), giant circulating platelets observed on a peripheral blood smear (larger than 4 µm and 
being able to reach 10 mm, while normal platelets are 2-3 µm) (figure 2) and 
thrombocytopenia (between 1010 to 1011 platelets/l compared to 1.5x1011 to 4x1011 platelets/l 
in healthy persons) (Hadjkacem et al., 2010a; Lanza, 2006)  
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Fig. 2. Blood smear of a BSS patient demonstrating giant platelet (1), white blood cell (2) and 
red cell (3) 
BSS diagnosis is based mainly on aggregation test using an aggregometer since the platelets 
of patients aggregate normally in response to agonists such as adenosine diphosphate 
(ADP), collagen, epinephrine, arachidonic acid but they failed to aggregate in presence of 
ristocetin (figure 3). In addition, all BSS patients have decreased or absent expression of the 
GPIb-IX-V complex. For this reason, the diagnosis can be confirmed by flow cytometry 
using specific antibodies recognizing one or more proteins of the complex (figure 4) 
(Hadjkacem et al., 2010a; Ware et al., 1998). 
 
 
Fig. 3. BSS platelets aggregation 
The curve 1 and 2 showed an increasing of light transmission that indicates positive wave 
aggregation, so BSS platelets aggregate normally with ADP and collagen but failed to 
aggregate in presence of ristocetin (curve 3). 
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The GPIIb-IIIa complex, normally expressed on the platelets surface of healthy persons and 
BSS patients, serves as a positive control. Those specialized laboratory tests are essential to 
avoid confusion between BSS and other similar platelet disorders (Hadjkacem et al., 2010a). 
Based only on clinical manifestations, many patients had been erroneously diagnosed with 
immune thrombocytopenia and were treated with steroids without response (Sachs et al., 
2003). 
 
 
Fig. 4. Flow cytometric analysis of normal and BSS platelets. (Hadjkacem et al., 2010b) 
HIP8 is an antibody recognizing GPIIb-IIIa complex and serves as positive control. HIP1, 
MB45 and SZ2 are antibodies directed against different epitope on GPIbα. We have used 
simultaneously two antibodies for each platelets marking: the HIP8 and one of the GPIbα 
antibodies. The result is considered as double positive when the fluorescence is observed in 
the square 2 and it is considered as only HIP8 positive when fluorescence exist in square 1. If 
the fluorescence is localized in the square 3, we concluded that the GPIbα antibody failed to 
bind to the specific protein. 
For healthy person, response is positive with all antibodies but in BSS patient, anti-GPIbα 
failed to bind on platelets surface because the absence of this protein. 
4.2.5 Transmission mode 
The BSS is an inherited disorder usually transmitted in an autosomal recessive manner and 
occurring in persons whose parents are close relatives. Both male and females are concerned 
by this disease; the male/female ratio is 1:1. An autosomal dominant with heterozygous 
state has also been found but rarely reported. This form was characterized by mild or no 
clinical symptoms and normal in vitro platelet function (Miller et al., 1992; Savoia et al., 
2001). 
Genetic counselling is done according to established standards for all autosomal recessive 
diseases.  
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4.2.6 Frequency 
BSS is a rare disease, the frequency of homozygous has been estimated to be approximately 
one in one million (Lopez et al., 1998) and, according to the Hardy-Weinberg Law, the 
frequency of heterozygotes is 1 in 500 (Savoia et al., 2001). 
4.2.7 Canditates genes 
Molecular investigations of numerous BSS patients showed that only three genes are 
responsible of the disease: GPIbα, GPIbβ, and GPIX. No mutations have been reported in 
the GPV gene (Moran et al., 2000). These genes belong to the leucine-rich family of proteins 
and are exclusively expressed in megakaryocytes and platelets lineage. They showed 
common structural features except for their different chromosomal locations (Table 3). All 
candidate genes are present in monocopie. They are relatively poor in intron and contain 
their open reading frame (ORF) and the 3'UTR in a single exon except the GPIbβ where the 
ORF is contained in two exons (Antonucci et al., 2000; Lopez et al., 1998). GPIbα and 
GPIX genes shared promoter consensus sequences especially GATA and ETS sites (Mayumi 
et al., 1994). 
 
 GPIbα 
 
GPIbβ GPIX 
Size of 
mRNA (kb) 
2.5 1 1 
Number of 
exons 
2 2 3 
Number of 
coding exons 
1 2 1 
Chromosome 
localization 
17-p12 22-q11.2 3q-21 
Table 3. Characteristics of BSS candidates genes  
4.2.8 BSS mutations 
Until now, more then fifty mutations responsible for BSS have been described: 25 mutations 
in the gene GPIbα, 18 mutations in GPIbβ and 11 in GPIX. These defects can be classified 
into three groups (table 4): 
- missense mutations or short deletions, often  resulting in abnormal and/or unsuitable 
complex with a significant reduction of protein expression on the platelets surface.  
- nonsense mutations giving truncated subunits, often without the transmembrane domain.  
- frameshift insertions or deletions leading to a new polypeptide with premature stop 
codon (Hadjkacem et al., 2010a; Lanza, 2006).  
 
Gene Missense mutation Nonsense 
mutations 
Frameshift 
or short deletions 
Others 
GPIbα 10 3 11 1 
GPIbβ 9 4 3 2 
GPIX 9 1 1 0 
Table 4. Different type of mutations described in literature in each BSS candidate gene 
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Compound heterozygote has been also described in BSS patients. It was relatively frequent 
as approximately 1/5 of described BSS mutations are of this form (Hadjkacem et al., 2010a). 
The genetic defects observed in BSS patients affect the von Willebrand binding site on 
GPIbα, inhibit the association between GPIbβ and GPIX after protein synthesis, or affect 
post-translational modifications that may influence the function of the complex.  
In very few cases, a point mutation predominantly affects receptor function as some 
described mutations in GPIbα and GPIX (Antonucci et al., 2000). 
4.2.9 BSS founder mutations  
Most mutations affect only one patient or one family but few exceptions do exist, such as the 
Asn45Ser identified in GPIX in several families from different nations (Koskela et al., 1999), 
Ala156Val in GPIbα frequently observed in Italian families (Budarf et al., 1995) and a 
recently identified Tunisian mutation (Hadjkacem et al., 2009, 2010). 
Bernard Soulier syndrome was the focus of several studies in European, Japanese and 
North American populations. African and Arab populations have not been studied, with 
few exceptions. Our laboratory studied this syndrome for the first time in Tunisia. 
Initially, our study concerned only one family consisting of five members: parents and three 
children including a boy suffering from BSS. Intermarriage increased the risk of developing 
the disease. We have identified a novel mutation in GPIbβ gene responsible for BSS 
in this family. The Ser23Stop so identified can be followed by MnlI restriction analysis of 
PCR amplified fragment. It is inherited as an autosomal recessive manner. Studies of protein 
expression of GPIb-IX-V complex showed the absence of GPIbα on the platelets surface of 
the patient (Hadjkacem et al., 2009).  
Subsequently, our study included two other unrelated Tunisian families with BSS cases. In 
one of these families, we have revealed the same Ser23Stop mutation while in the second we 
observed compound heterozygosity including Ser23Stop in addition to two others missense 
mutations located in GPIbβ gene: Asp51Gly and Ala55Pro (Hadjkacem et al., 2010b).   
Given that most of described BSS mutations are unique and the same Ser23Stop 
mutation being found in three unrelated Tunisian families, we suggested that it is an ancient 
mutation having a founder effect and can be used in genotyping for BSS diagnosis in further 
exploration of other Tunisian families. Indeed, the identification of a founder mutation can 
help physicians to avoid misdiagnosis. 
4.2.10 Treatment 
The severity of bleeding is unpredictable in the BSS, however most patients require 
transfusion in case of excessive bleeding (Nurden, 2005). The benefits of receiving the 
transfusions must be evaluated against the risks of exposure. Repeated exposure to blood 
products raises concern for alloimmunization and platelet refractoriness. Although some 
authors have suggested that patients should receive platelets from human leukocyte 
antigen–matched donors in order to avoid alloimmunization (Balduini et al., 2002), 
Some patients should be warned to avoid trauma and antiplatelet drugs such as aspirin, to 
maintain dental hygiene and use of contraceptive devices to puberty (Lanza, 2006).  
The administration of rFVIIa and Desmopressin is used to shorten the bleeding time in some 
patients. In rare cases of patients with serious and repetitive bleeding, bone marrow 
transplantation is used (Lanza, 2006). 
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5. Conclusion 
The inherited platelet disorders are functional abnormalities of platelets due to genetic 
defects and lead to bleeding symptoms of varying severity. They constitute a large group of 
rare diseases caused by one or more mutations affecting one or more genes. These genetic 
defects may affect platelet granules or proteins involved in signaling pathways. 
Nevertheless, diseases caused by abnormalities of platelet membrane receptors are the best 
known platelets diseases especially the Glanzmann thrombasthenia and the Bernard Soulier 
syndrome. Their diagnosis is relatively easy to perform but they are manifested by severe 
bleeding.  
Despite advances in the understanding of the etiology of these deseases, usually the 
underlying mechanisms remain unknown and treatment is relatively rudimentary. 
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